8-K: Cardio Diagnostics Holdings Completes $1 Million Private Placement

Cardio Diagnostics Holdings has successfully closed a private placement, issuing units consisting of common stock and warrants, raising $1 million for working capital and general corporate purposes.

Summary

• Cardio Diagnostics Holdings completed a private placement on February 2, 2024, raising $1 million.
• The company issued 561,793 units to 7 accredited investors, with each unit containing one share of common stock and one warrant.
• The warrants have an exercise price of $1.78 per share and are exercisable for six years.
• The company intends to register the shares for resale within 180 days.
• The net proceeds will be used for working capital and general corporate purposes.
• Altitude Capital Group acted as the placement agent and received a 10% cash commission and warrants to purchase 112,353 shares at $1.78 per share.
• The private placement was exempt from registration under the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company successfully raised capital, but the terms include commissions and potential dilution. The need for working capital suggests the company is not yet self-sustaining.

Positives

• The company successfully raised $1 million in a private placement.
• The funds will be used for working capital and general corporate purposes.
• The company intends to register the shares for resale within 180 days, providing liquidity to investors.
• The company has secured additional funding through the private placement.

Negatives

• The company incurred a 10% cash commission to the placement agent, reducing the net proceeds.
• The company issued warrants to the placement agent, which could dilute existing shareholders if exercised.
• The private placement was conducted as an unregistered offering, limiting the pool of potential investors.

Risks

• The company's ability to successfully register the shares for resale within 180 days is not guaranteed.
• The exercise of warrants could dilute existing shareholders.
• The company's reliance on private placements for funding may indicate challenges in accessing public markets.
• The company's chairman has a 10% ownership interest in the placement agent, which could present a conflict of interest.

Future Outlook

The company intends to register the shares of common stock and the common stock issuable upon exercise of the warrants for resale within 180 days. The company also intends to afford the private placement investors the right to participate in future company financings through February 2, 2025, with some exceptions.

Management Comments

• The company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes.

Industry Context

Private placements are a common method for smaller companies to raise capital, especially when access to public markets is limited. The use of warrants is also a typical incentive for investors in such offerings. The company's need for working capital suggests it is in a growth phase or facing operational challenges.

Comparison to Industry Standards

• The 10% cash commission paid to the placement agent is within the typical range for private placements of this size.
• The inclusion of warrants is a common practice to incentivize investors in private placements, particularly for early-stage companies.
• The six-year term for the warrants is relatively standard, providing investors with a longer-term upside potential.
• The exercise price of $1.78 per share is consistent with the unit price, indicating a fair valuation at the time of the offering.
• Comparable companies in the biotech or diagnostics space often use private placements to fund research and development or commercialization efforts.

Related Party Transactions

• Warren Hosseinion, M.D., the company's Chairman of the Board, holds a 10% ownership interest in Altitude Capital, the placement agent.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• Investors in the private placement will have the opportunity to resell their shares after registration.
• The company will have additional working capital to support its operations.
• The company's employees may benefit from the increased financial stability.

Next Steps

• The company will register the shares for resale within 180 days.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will continue to operate and develop its business.

Key Dates

Keywords

private placement, warrants, common stock, capital raise, accredited investors, placement agent, securities offering, working capital, resale registration